EP Patent

EP2335735A1 — Pharmaceutical composition for treatment of dry eye syndrome

Assigned to Novaliq GmbH · Expires 2011-06-22 · 15y expired

What this patent protects

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble drug substance…

USPTO Abstract

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble drug substances with immunosuppressant activity. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP2335735A1
Jurisdiction
EP
Classification
—
Expires
2011-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.